Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
A Differentiated Next-Generation GLP Candidate SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA pathway
Tirzepatide is a dual-agonist it acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
However, the treatment landscape has seen significant changes in the past five years, with several late-phase candidates in development
Contact your prescriber sooner if you notice these changes Do not wait for the next routine follow-up if you develop: Chest pain, marked palpitations, or shortness of breath A sharp rise in anxiety, agitation, or irritability Insomnia that starts impairing daytime function Meaningful appetite suppression with weight loss or skipped meals Feeling emotionally flat, unlike yourself, or unusually driven in a way that feels unhealthy Those reports help guide treatment
Individual risk stratification informed by genetic predispositions and biomarkers supports safer, more personalized decision-making
US$ 26.79
US$ 29.84
US$ 23.21
US$ 21.81
US$ 28.64
